Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Breath Metabolomics of Placebo Effects, a Pilot Study (BMPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04956718
Recruitment Status : Completed
First Posted : July 9, 2021
Last Update Posted : March 15, 2022
Sponsor:
Collaborator:
Swiss National Science Foundation
Information provided by (Responsible Party):
University Children's Hospital Basel

Brief Summary:
This study is to analyze the breath metabolome before and after the administration of a placebo in an established experimental pain procedure in healthy subjects in order to investigate placebo effects, and whether they induce any measurable changes at the metabolic level.

Condition or disease Intervention/treatment Phase
Analgesia Other: Cold Pressor Test (CPT) Other: Placebo NaCl Nasal spray Not Applicable

Detailed Description:
Interrogation of the exhaled breath metabolome will be performed by using an objective method of measurement for placebo effects in pain analgesia, known as Cold Pressure Test (CPT). CPT reactions can be measured objectively by blood pressure spikes as well as changes in continuous heart rate monitoring.To this end, probands will be continuously connected to a Heartrate & Blood Pressure Monitor. First, baseline exhalation will be assessed. Then, the CPT is performed according to the 'CPT Guide' with subsequent post-pain exhalations analysis with or without self-administration of the placebo (NaCl nasal spray). After 15 minutes rest, probands will be submitted to a second post-pain exhalations set (+/- placebo). The process is completely non-invasive as the participant just exhales through a commercially available disposable bacterial/viral filter coupled to the ion source.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Single centered; national ,randomized, crossover, pilot study
Masking: Single (Participant)
Masking Description: participants do not know its a placebo
Primary Purpose: Basic Science
Official Title: Breath Metabolomics of Placebo Effects Via Cold Pressor Test
Actual Study Start Date : October 21, 2021
Actual Primary Completion Date : January 26, 2022
Actual Study Completion Date : January 26, 2022

Arm Intervention/treatment
CPT first

Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.

All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa.

Other: Cold Pressor Test (CPT)
Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.

Other: Placebo NaCl Nasal spray
placebo nasal spray containing NaCl solution

CPT+placebo first

Participant will be told and read about the 'pain medication' (= Placebo NaCl Nasal spray). Thereafter participant will self-administer a nasal spray, which is in fact a placebo nasal spray containing NaCl solution and Cold Pressor Test (CPT) is performed.

All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa

Other: Cold Pressor Test (CPT)
Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.

Other: Placebo NaCl Nasal spray
placebo nasal spray containing NaCl solution




Primary Outcome Measures :
  1. change in signal intensity of mass-to-charge ratio (m/z) of exhaled metabolites [ Time Frame: 1 hour ]
    The variable of primary interest is the variation of signal intensity of mass-to-charge ratio (m/z) of exhaled metabolites.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy female and male adult volunteers
  • German speaking, or good knowledge of the German language
  • Able to understand the study
  • Able to give informed consent

Exclusion criteria:

  • Regularly taking medication potentially interfering with pain sensation (analgesics, antihistamines and calcium and potassium channel blockers)
  • Current pregnancy
  • Daily smokers (as per WHO definition: A daily smoker is someone who smokes any tobacco product at least once a day.)
  • Neuropathy
  • Chronic pain
  • Neuromuscular or psychiatric disease
  • Known or suspected heart, kidney or liver disease
  • Hypertension (Systolic (mmHg) >130, Diastolic (mmHg) >80)
  • History of fainting or seizures
  • History of Frostbite
  • Current medications (psychoactive medication, narcotics, intake of analgesics) or being currently in psychological or psychiatric treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04956718


Locations
Layout table for location information
Switzerland
Universitäts-Kinderspital beider Basel (UKBB)
Basel, Basel-Stadt, Switzerland, 4056
Sponsors and Collaborators
University Children's Hospital Basel
Swiss National Science Foundation
Investigators
Layout table for investigator information
Principal Investigator: Pablo Sinues, Prof. Dr. Universitäts-Kinderspital beider Basel (UKBB)
Layout table for additonal information
Responsible Party: University Children's Hospital Basel
ClinicalTrials.gov Identifier: NCT04956718    
Other Study ID Numbers: 2021-01132; ks21Sinues
First Posted: July 9, 2021    Key Record Dates
Last Update Posted: March 15, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Children's Hospital Basel:
pain
placebo effects
analgesia
placebo analgesia
cold pressor test
breath metabolomics